Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 25, 2019 in Breast cancer | 0 comments

In a nutshell

This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer. 

This study concluded that these side effects do not impact the outcomes for these patients.  

Some background

Ado-trastuzumab emtansine (T-DM1; Kadcyla) is a targeted therapy. It is used as a single agent to treat HER2+, metastatic breast cancer (BC). T-DM1 is generally well tolerated by patients with HER2+ advanced BC. 

Adverse events (AE’s) are side effects of treatment. They can sometimes lead to treatment doses being adjusted or treatment being stopped completely depending on the severity of AEs. It was not known if AEs requiring T-DM1 dose interruption or reductions would lead to altered outcomes for patients with HER2+ advanced metastatic BC.  

Methods & findings

This study involved 893 patients with HER2+ advanced metastatic BC who received T-DM1 treatment. AEs during the first 4 months leading to dose interruption or reduction were recorded. The effect of this on overall survival (OS) and progression-free survival (PFS) was monitored.   

AEs requiring T-DM1 dose interruptions or reductions within the first 4 months of treatment were not significantly associated with OS or PFS. 

The bottom line

This study concluded that early AEs requiring T-DM1 dose interruptions or reductions did not lead to an altered long-term OS or PFS. 

Published By :

Breast Cancer Research and Treatment

Date :

Aug 09, 2019

Original Title :

Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.

click here to get personalized updates